CIMETIDINE tablet, film coated

Land: USA

Sprog: engelsk

Kilde: NLM (National Library of Medicine)

Aktiv bestanddel:

CIMETIDINE (UNII: 80061L1WGD) (CIMETIDINE - UNII:80061L1WGD)

Tilgængelig fra:

REMEDYREPACK INC.

Indgivelsesvej:

ORAL

Recept type:

PRESCRIPTION DRUG

Terapeutiske indikationer:

Cimetidine tablets are indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine tablets at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION: Duodenal Ulcer). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of cimetidine tablets and antacids is not recommended, since antacids have been reported to interfere with the absorption of cimetidine. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine tablets 400 mg at bedtime for periods of up to 5 years. 3. Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. 4. Erosive gastroesophageal reflux (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for

Produkt oversigt:

Cimetidine Tablets, USP are available containing 200 mg, 300 mg, 400 mg or 800 mg of cimetidine, USP. The 200 mg tablets are green, film-coated, five-sided, house-shaped, unscored tablets debossed with M on one side and 53 on the other side. They are available as follows: NDC: 70518-2809-00 PACKAGING: 30 in 1 BLISTER PACK Repackaged and Distributed By: Remedy Repack, Inc. 625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762 Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from light. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

Autorisation status:

Abbreviated New Drug Application

Produktets egenskaber

CIMETIDINE- CIMETIDINE TABLET, FILM COATED
REMEDYREPACK INC.
----------
DESCRIPTION
Cimetidine is a histamine H
-receptor antagonist. Chemically it is _N"_-cyano- _N_-methyl-
_N'_-[2-[[(5-methyl-1 _H_-imidazol-4-yl)methyl]thio]-ethyl]guanidine.
Its structural formula is:
Cimetidine contains an imidazole ring, and is chemically related to
histamine.
Cimetidine has a bitter taste and characteristic odor.
SOLUBILITY CHARACTERISTICS
Cimetidine is soluble in alcohol, slightly soluble in water, very
slightly soluble in
chloroform and insoluble in ether.
Each tablet, for oral administration, contains 200 mg, 300 mg, 400 mg
or 800 mg
cimetidine, USP. Inactive ingredients are: croscarmellose sodium,
crospovidone,
hypromellose, lecithin, magnesium stearate, microcrystalline
cellulose, polydextrose,
polyethylene glycol, povidone, pregelatinized starch (corn), sodium
alginate, sodium
lauryl sulfate, titanium dioxide, triacetin, vanillin, FD&C Blue No. 1
Aluminum Lake, FD&C
Yellow No. 6 Aluminum Lake and D&C Yellow No. 10 Aluminum Lake.
CLINICAL PHARMACOLOGY
Cimetidine tablets competitively inhibits the action of histamine at
the histamine H
receptors of the parietal cells and thus is a histamine H
-receptor antagonist.
Cimetidine is not an anticholinergic agent. Studies have shown that
cimetidine tablets
inhibit both daytime and nocturnal basal gastric acid secretion.
Cimetidine tablets also
inhibit gastric acid secretion stimulated by food, histamine,
pentagastrin, caffeine and
insulin.
ANTISECRETORY ACTIVITY
_1) ACID SECRETION_
_Nocturnal_
An 800 mg oral dose of cimetidine tablets at bedtime reduces mean
hourly H
activity
2
2
2
+
by greater than 85% over an 8-hour period in duodenal ulcer patients,
with no effect on
daytime acid secretion. A 1,600 mg oral dose of cimetidine tablets at
bedtime produces
100% inhibition of mean hourly H
activity over an 8-hour period in duodenal ulcer
patients, but also reduces H
activity by 35% for an additional 5 hours into the following
morning. Cimetidine tablets given as 400 mg twice dai